Access cutting-edge epilepsies treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Preparing your pre-screening questions…
Access epilepsies specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related epilepsies treatment provided free
Check if you qualify for this epilepsies clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study will test computer programs that help doctors read brain MRI scans. The programs use artificial intelligence (AI). The study includes people with epilepsy, a condition that causes repeated seizures. Brain changes linked to epilepsy can be hard to see on an MRI (magnetic resonance imaging) scan. Different doctors may read the same scan in different ways. The researchers want to build AI tools that help doctors find these changes earlier. Earlier findings could lead to a faster diagnosis. They could also help doctors decide if a genetic test or a brain surgery evaluation is right for a patient. The researchers also want to learn if AI can predict how well epilepsy surgery will work. If it can, surgeons could use the tool to plan an operation. The goal is to stop seizures while protecting parts of the brain that control speech and sight. Who can take part? People with epilepsy who are treated at the Gaslini Institute or another study center Adults who give their own written consent Children whose parent or caregiver gives written consent People who do not agree to take part cannot be included. What will happen? The researchers will collect brain MRI scans from about 2,000 people. The scans come from regular clinical care. The researchers will replace each person's name on the scan with a code number. The coded scans go to a secure online portal. Study centers around the world share this portal. One trained researcher will run the AI programs on the scans. The researchers will keep the scans for 2 years to build an image library. The researchers will compare the scans with health information. They want to find signs in the scans that show how epilepsy may change over time. This study does not test a new medicine or treatment. It will last about 2 years.
Sponsor: Istituto Giannina Gaslini
Yes, this clinical trial (NCT07881185) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for epilepsies treatment options in Philadelphia, PA, this clinical trial (NCT07881185) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced epilepsies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.